Objective: To evaluate effectiveness of MiniMed™ AHCL on outcomes of study participants with different glycemic management challenges.
Methods: Adults (N=128, ≥18 years) with T1D from 16 investigational sites, underwent baseline run-in (~2wks) of continuous subcutaneous insulin infusion (CSII), sensor-augmented pump (SAP) or HCL therapy, followed by study period (3 months) with MiniMed™ AHCL. In this exploratory analysis, participants with different baseline glycemic characteristics (mean SG and SD of SG) were identified using Hierarchical Clustering Analysis with Ward’s method and stratified into 5 cohorts. AHCL glycemic outcomes were evaluated and compared to run-in outcomes.
Results: After AHCL initiation, overall glycemic control improved regardless of baseline glycemic characteristics (i.e., low-to-high mean SG and SD of SG) (Table). As expected, those from Cluster 5 with highest baseline mean SG and SD of SG improved the most. While those from Cluster 1 with lowest baseline mean SG and SD of SG achieved the highest TIR. Although those from Cluster 2 achieved better glycemic outcomes compared to their baseline, they didn’t outperform those from Cluster 3, possibly due to their higher SD of SG and less aggressive carb ratio.
Conclusion: Improved glycemic control was observed with MiniMed™ AHCL regardless of glycemic conditions at baseline.
J.Shin: Employee; Medtronic. Z.Dai: Employee; Medtronic. F.Niu: None.
